October 13, 2020 -- Axol Biosciences has added multielectrode array (MEA) screening services for human-induced pluripotent stem cell (hiPSC)-derived cells to its service offering for preclinical drug discovery.
The company said that its new MEA screening services optimize hiPSC-derived cell culture, while also providing electrophysiology acquisition and analysis from physiologically relevant human cell models.
The expansion combines Axol's hiPSC-derived human cells and electrophysiological experience with Axion Biosystems' Maestro Pro MEA platform, according to the firm. The Maestro Pro supports continuous label-free and real-time data acquisition and analysis from 768 electrodes in up to a 96 wp format, Axol said.
Copyright © 2020 scienceboard.net